GLP-1 drugs and PCOS weight loss: what TikTok gets right and wrong

What's this video probably claiming?

Based on the caption, hashtags, and the #mochipartner tag, this is almost certainly a paid partnership post featuring a before-and-after weight loss transformation tied to GLP-1 medication prescribed through Mochi Health. The PCOS hashtag suggests the creator or her subject has polycystic ovary syndrome, and the framing implies GLP-1 therapy helped drive meaningful weight loss in someone with that condition. The emotional framing, "I'm so proud of her," positions this as a success story rather than a clinical explainer. The $40 discount link in bio is a classic affiliate conversion play. So the implied claims are roughly: GLP-1 medication works for PCOS-related weight gain, Mochi Health is a trustworthy access point, and this transformation is achievable for viewers who sign up. None of that is necessarily false, but each piece deserves more scrutiny than a 60-second TikTok can give it.

What does the science actually show?

GLP-1 receptor agonists do have a legitimate evidence base for weight loss in people with PCOS, though the research is still maturing. A 2023 randomized controlled trial by Jensterle et al. published in Obesity found that semaglutide 1 mg weekly produced significantly greater weight reduction than liraglutide 1.2 mg daily in women with PCOS over 24 weeks, with semaglutide users losing roughly 9.5 kg versus 7.4 kg. A 2022 review by Tay et al. in Frontiers in Endocrinology noted GLP-1 agonists improve insulin resistance and androgen levels in PCOS beyond what weight loss alone explains, which is clinically meaningful. The SCALE trial data on liraglutide 3 mg showed about 5-6 percent greater body weight reduction versus placebo over 56 weeks. Tirzepatide data from the SURMOUNT-1 trial showed up to 22.5 percent mean body weight reduction at the highest dose, though PCOS-specific subgroup data is limited. These are real effects. The problem is they depend heavily on sustained use, dietary adherence, and individual metabolic response.

Where does the social media noise diverge from clinical reality?

Before-and-after videos strip out the full picture almost by design. What they rarely show: side effect profiles that cause 5 to 10 percent of patients to discontinue therapy within the first few months (nausea, vomiting, gastroparesis risk), the fact that weight typically returns after stopping the medication, per a 2022 Wilding et al. follow-up in Diabetes, Obesity and Metabolism showing two-thirds of lost weight regained within a year of stopping semaglutide, and the cost and access barriers for uninsured patients. Mochi Health operates as a telehealth prescriber, which is legal and can be legitimate, but the $40 discount affiliate link blurs the line between health content and direct-to-consumer pharmaceutical marketing. The FTC has flagged similar arrangements in other categories. The PCOS framing also tends to imply GLP-1 drugs are approved specifically for PCOS treatment. They are not. Any use for PCOS is off-label. That distinction matters for informed consent, and it is almost never mentioned in these posts.

What should you actually know?

If you have PCOS and are considering GLP-1 therapy, there are genuinely good reasons to talk to a clinician about it. The mechanistic rationale is solid: GLP-1 agonists reduce hyperinsulinemia, which is a central driver of androgen excess in many PCOS presentations. But a TikTok transformation video is not a clinical consult. Ask your provider specifically whether semaglutide or tirzepatide is appropriate for your metabolic profile, not just your weight. Understand that insurance coverage for obesity indications is inconsistent and that compounded semaglutide, often cheaper and widely marketed by telehealth platforms, is not FDA-approved and carries formulation quality concerns the FDA has flagged directly. Check whether the platform prescribing your medication has board-certified endocrinologists or obesity medicine specialists in the loop, not just general practitioners approving scripts at volume. The weight loss is real in many cases. The full clinical picture is more complicated than any before-and-after can convey.